首页> 美国卫生研究院文献>Internal Medicine >3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis

【2h】

3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis

机译：3A比较R-THP-COP和R-CHOP方案治疗老年弥漫性大B细胞淋巴瘤的单机构分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective We retrospectively compared the clinical efficacy and toxicity of rituximab (R)-THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) with that of R-CHOP (rituximab, adriamicin, cyclophosphamide, vincristine, and prednisolone) in previously untreated old patients with diffuse large B-cell lymphoma (DLBCL).

机译：目的我们回顾性比较利妥昔单抗（R）-THP-COP（吡柔比星，环磷酰胺，长春新碱和泼尼松龙）与R-CHOP（利妥昔单抗，阿德里亚霉素，环磷酰胺，长春新碱和泼尼松龙）的临床疗效和毒性弥漫性大B细胞淋巴瘤（DLBCL）患者。

著录项

期刊名称 Internal Medicine
作者
Hiroaki Araie; Ippei Sakamaki; Yasufumi Matsuda; Katsunori Tai; Satoshi Ikegaya; Kazuhiro Itoh; Shinji Kishi; Kana Oiwa; Miyuki Okura; Toshiki Tasaki; Naoko Hosono; Takanori Ueda; Takahiro Yamauchi;
展开▼
作者单位

展开▼
年(卷),期 2017(56),18
年度 2017
页码 2407–2413
总页数 7
原文格式 PDF
正文语种
中图分类基础医学;
关键词
diffuse large B cell lymphoma R-CHOP R-THP-COP pirarubicin old patients;

机译：弥漫性大B细胞淋巴瘤;R-CHOP;R-THP-COP;吡柔比星;老年患者;

相似文献

外文文献
中文文献
专利

1. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis [J] . Hiroaki Araie, Ippei Sakamaki, Yasufumi Matsuda, Internal medicine. . 2017,第18期

机译：3A比较R-THP-COP和R-CHOP方案治疗老年弥漫性大B细胞淋巴瘤的单机构分析
2. Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens [J] . Fangwen Zhang, Ling Li, Lei Zhang, Blood and Lymphatic Cancer: Targets and Therapy . 2019,第1期

机译：EPOCH联合利妥昔单抗/ R-CHOP方案治疗双发性弥漫性大B细胞淋巴瘤CD5表达的预后分析和疗效比较
3. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study [J] . Yamamoto Masahide, Watanabe Ken, Fukuda Tetsuya, Anticancer Research: International Journal of Cancer Research and Treatment . 2017,第5期

机译：初始R-Chop治疗后，弥漫性大B细胞淋巴瘤难以或在第一次复发中预测预后预测：单机制研究
4. Pathological Analysis of Diffuse Large B-Cell Lymphoma and Clinical Treatment with Chinese and Western Medicine [C] . Xianhui Liu, Xiaona Guo, Chunsheng Yan International Conference on Management, Education, Information and Control . 2016

机译：弥漫性大B细胞淋巴瘤的病理分析及中西医临床治疗
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens [O] . Fangwen Zhang, Ling Li, Lei Zhang, 2019

机译：EPOCH联合利妥昔单抗/ R-CHOP方案治疗双发性弥漫性大B细胞淋巴瘤CD5表达的预后分析和疗效比较
7. >Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens [O] . Fangwen Zhang, Ling Li, Lei Zhang, 2019

机译：>用剂量调整时代巨枝加中荷敏/ R-CHOC型患者双击弥漫性大B细胞淋巴瘤CD5表达的预后分析及疗效比较。

3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis

摘要

著录项

相似文献

相关主题

期刊订阅